Nestle Health Science (NHSc) Exercises its Exclusive WorldWide Option to License CDX-6114 from Codexis

 Nestle Health Science (NHSc) Exercises its Exclusive WorldWide Option to License CDX-6114 from Codexis

Nestle Health Science (NHSc) Exercises its Exclusive WorldWide Option to License CDX-6114 from Codexis

Shots:

  • Codexis to receive $3M milestone and NHSc to get exclusive WW rights to develop and commercialize Codexis’s CDX-6114 for phenylketonuria (PKU)
  • In 2017, Codexis & NHSc collaborated to develop CDX-6114 using Codexis’ CodeEvolver protein engineering platform paying $14M upfront and future milestones and granted an option to license for CDX-6114 to NHSc 
  • Codexis’s CDX-6114 is an enzyme involved in converting amino acid phenylalanine into tyrosine prevents further phenylalanine toxicity. CodeEvolver is a protein technology used for the development of therapies & proteins in multiple applications

Click here to read full press release/ article | Ref: Codexis | Image: Arab News

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post